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A B S T R A C T
Metastatic bony lesions involving proximal femur and hip joint pose a challenge to orthopedic surgeons. Lesions
in this important weight-bearing zone of the femur weaken its ability to sustain load causing pain and impending
pathologic fracture. These Patients warrant multidisciplinary approach including orthopedic surgeons, oncolo-
gist and medical specialties. Management of these lesions has evolved over the last 60 years from benign neglect
to internal fixation and recently to prosthetic reconstruction for optimum function. Decision for surgical ap-
proach requires consideration for location of the lesion, presence of a fracture, tumor type, cortical destruction,
patient's life expectancy, patient preferences and the expected outcome. We aim to present a narrative review of
the options and results of surgical management of these lesions in the light of literature.
1. Introduction
Metastatic lesions of the proximal femur and hip joint are common
and present with multiple management issues. Management involves
general care physicians, medical oncologists and reconstructive hip
surgeons. These lesions frequently arise from breast, prostate, lung,
renal, and thyroid carcinomas [1–3]. The tumor that metastasizes to the
hip with the greatest frequency is carcinoma of the breast [4–6] Pa-
thologic lesions in this important weight-bearing zone weaken its
ability to sustain load causing pain and impending pathologic fracture.
It is estimated that 40% of patients with pathologic fractures survive for
at least 6 months after their fracture, and 30% survive for more than 1
year [7,8]. Management of these lesions varies from benign neglect to
internal fixation and recently to prosthetic reconstruction for optimum
function. This article aim to focus on metastatic tumors of the hip and
proximal femur and present a narrative review of surgical management
options of this unique clinical entity.
2. Historical perspective
The management of metastatic hip lesions has evolved considerably
over the past 60 years. Use of light traction was the most primitive form
of treatment. Coley and Higinbotham [11] initially reported that pa-
thologic fractures could be prevented by the use of calliper splints to
decrease the load on the affected bone. Their emphasis then shifted to
identifying and treating symptomatic lesions before fracture. In 1950,
tumor resection and replacement with bulk allograft was reported with
favourable outcome for tumors involving the upper extremity [12].
Internal fixation of impending or actual fractures also became popular
at the same time. However, failed internal fixation of pathologic fe-
moral neck fractures led Francis et al., [13] in 1962, to advocate re-
section of the femoral head and neck as a primary treatment for lesions
involving those structures. They believed that resection would provide
rapid pain relief and quicker rehabilitation and it will help reducing
surgical complications. They reported good outcome of their 19 pa-
tients in the series. In 1976, Harrington started advocating the use of
polymethyl methacrylate (PMMA) cement as an adjunct to internal
fixation in patients with bone loss in metastatic disease. In a series of
375 patients, Harrington et al. [14] excised the lesion and then per-
formed internal fixation or prosthetic replacement and reinforcement
with PMMA. He reported 94% ambulation rate in his series.
In 1980, Lane et al. [15] reported endoprosthetic replacement for
pathologic lesions of the hip. Impending fracture and a life expectancy
of more than 1 month was considered adequate indication for surgical
intervention. Good to excellent results were obtained in all of the pa-
tients treated with either an Austin- Moore Hemiarthroplasty or a total
hip replacement. In 1981, Harrington [16] reported on the use of total
hip prostheses in patients with acetabular lesions. Harrington designed
a larger acetabular component that would distribute the mechanical
load to areas of less involved bone. Current management of these le-
sions focuses on thorough assessment and surgical intervention leading
to quick rehabilitation and successful long-term reconstructive strategy.
3. Evaluation and planning
Metastatic lesion of the Hip and the femur are seen in a variety of
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situations. Presentation can vary from patients presenting with Hip pain
in the outpatient clinic, as a specialist referral to Hip surgeon or as
pathological fracture to the emergency on call orthopedic surgeon.
A thorough, multi-disciplinary pre-operative evaluation is indicated
to avoid decision-making errors. Complete history and physical ex-
amination, appropriate serology, skeletal survey, bones scan, and
computed tomography of the chest, abdomen, and pelvis will identify
the vast majority of primary tumors for a suspected metastatic lesion.
The investigation should include a medical oncologist, internist, and
potentially a radiation oncologist. Biopsy may be indicated if a primary
source cannot be identified [17,18]. A full discussion of the evaluation
and treatment of a primary bone malignancy or unknown primary is
beyond the scope of this review. For clarity, we will discuss bony lesions
around the hip and will focus on the surgical decision-making centered
on internal fixation or arthroplasty.
Pre-operative medical optimization is always recommended, as
these patients usually present with generalized weakness and metabolic
issues including, hypercalcemia or coagulopathy [19]. It is important
for surgeon and the patient to consider remaining life expectancy and
other medical issues before any operative intervention. Involvement of
medical oncologist helps to establish the prognosis of the disease and
possible role of chemotherapy or radiotherapy can be considered for
better disease control and to optimize time for surgical intervention.
Patients presenting with impending pathological fracture warrant
quicker assessment and early intervention [17,18]. Various methods of
predicting the risk of fracture have been proposed. The Mirel's criterion
is most commonly used (Table 1). The score is based on nature of the
lesion, anatomic location, size, and assessment of functional pain [20].
The higher the score, greater is the risk of fracture. For example, lesions
with scores of eight or higher would be treated with internal fixation (a
lytic, painful sub trochanteric lesion), while lesions with lower scores (a
painful, small lesion in the shaft of the radius) would be considered
candidates for radiation treatment [21]. Obviously, lower extremity
lesions with functional pain have a high rate of fracture and should
probably be treated with prophylactic internal fixation.
Patients with a single Hip lesion and an unknown known primary
tumor need to be evaluated with caution. Primary bone tumors, such as
chondrosarcoma, typically present in the hip area and it is not un-
common for patients to undergo hip replacement or insertion of an
intramedullary device and the pathologist subsequently reporting a
primary bone sarcoma [22].
Preoperative embolization is recommended before surgery in cases
of metastatic renal and thyroid cancer [9,10]. These tumors are highly
vascular, and hemorrhage can complicate surgery. Embolization should
occur as close to the time of surgery as possible. Waiting longer than
twenty-four hours between embolization and surgery may produce fe-
vers, rigors, and diaphoresis related to tumor necrosis.
4. Current techniques
Surgical intervention for metastatic hip lesions helps to obtain
biopsy for diagnosis, alleviate pain and restore function. Ideally, these
patients should have one-time appropriately planned operative inter-
vention for optimum pain relief and quick functional rehabilitation.
Selection of surgical technique varies from open reduction and fixation
or intramedullary nailing of the pathologic fractures to prosthetic re-
placement of the diseased proximal femur and the Hip. Decision for
surgical approach requires consideration for location of the lesion
(Fig. 1), presence of a fracture, tumor type, cortical destruction, pa-
tient's life expectancy, patient preferences, and the expected outcome
[17–20]. Only a few studies have rigorously compared outcomes among
implant types [17,18]. A survey study of 98 orthopedic oncologists
demonstrated large variation in the physicians' preferred surgical stra-
tegies emphasizing the need for further study to improve understanding
of surgical outcomes [21].
Although preferences vary among surgeons, in general, a pathologic
fracture is treated surgically when the patient was expected to live
longer than 30 days. An impending fracture is also generally treated
surgically when the patient is expected to live longer than 30 days and
has substantial bone destruction or pain on load bearing. Obviously,
these lesions are best treated in the “impending-fracture” stage as there
is less functional loss and rehabilitation is quicker if the bone has not
broken [22,23].
4.1. Osteosynthesis
Patients with trochanteric or sub trochanteric lesions with preserved
head and neck of femur are amenable to stabilization with in-
tramedullary nails, plates or dynamic Hip screw fixation device.
Intramedullary nailing is primarily used in patients with limited bone
loss and trochanteric or sub-trochanteric lesions. While aiming to sta-
bilize the whole length of the femur with intramedullary nail, screw is
also passed through the nail into the head and neck of the femur to
minimise chances of future collapse and further surgical intervention
(Fig. 2). Open reduction and internal fixation (ORIF) is typically used in
patients with small focal lesions around the trochanteric area [24]
Pathological fractures or lesions are however, less likely to heal and
reoperation rate is therefore higher in this group of patients. Fracture
fixation or Stabilization is therefore preferred over prosthetic replace-
ment in patients with limited function or life expectancy of less then
Table 1
Mirel's Criteria for evaluating fracture risk for metastatic lesions.
Score
Variable 1 2 3
Site Upper Limb Lower Limb Peri-trochanteric
Pain Mild Moderate Activity
Activity/Nature Blastic Mixed Lytic
Size 1/3 1/3–2/3 > 2/3rd
Fig. 1. Illustration of the proximal femur demonstrating the anatomic areas for
consideration of surgical intervention. Area “a” consists of the isthmus to the
base of the femoral neck, “b” is the trochanteric region, and “c” is the sub
trochanteric region to 5 cm below the lesser trochanter. For lesions spanning
multiple areas, the area most affected by the lesion is primarily important for
surgical planning.
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three months [25]. Surgery in these cases is a palliative measure to
relieve pain, facilitate nursing care and is performed with or without
metastatic resection and bone cement augmentation for better stabili-
zation and quicker rehabilitation.
Osteosynthesis in metastatic lesions has been reported extensively.
Piccioli et al. [26] studied functional outcomes in a group of 80 patients
with the proximal femur pathologic fractures treated with a titanium
proximal nail. All patients in the study reported pain relief and im-
provement in the quality of life. However, based on the long term
follow up, authors concluded that intramedullary nail fixation may fail
requiring further surgical intervention and the procedure should be
reserved for patients with limited life expectancy. Steensma et al. [27]
reported implant exchange after failure with 6.1% of intramedullary
nailing procedures (5 of 82) and 42% of open reduction and internal
fixation procedures. Wedin and Bauer [28] demonstrated 13% failure
after intramedullary nailing and 25% after the use of a dynamic hip
screw for reduction and fixation of lesions in the proximal femur.
Osteosynthesis procedures are technically easier and can be per-
formed by general orthopedic surgeons. The other advantages include
less anaesthetic time and blood loss and can be performed in selected
group of patients with careful consideration of the location of the lesion
and overall medical condition and life expectancy of these patients.
4.2. Prosthetic reconstruction
Proximal femur resection and prosthetic reconstruction is preferred
in patients with extensive bone destruction, in patients with pathologic
fractures, in tumors resistant to radiation therapy and in patients with
more proximal metastatic lesions (Fig. 1). Use of custom and modular
proximal femoral endoprosthetic replacements in metastatic lesions
have been reported extensively [25–29]. It allows quicker rehabilitation
and minimise chances of further tumor-related problems such as non-
union and implants failures or exchange [29–32].
Lesions of the femoral head and neck region without acetabular
involvement can be treated by Hemiarthroplasty (Fig. 3). This proce-
dure is technically easier to perform, has less chance of hip dislocation
because of large femoral head size as and can provide a satisfactory
short-term functional outcome. Hemiarthroplasty however, is asso-
ciated with residual hip and thigh pain because of aseptic loosening and
acetabular wear. Although bipolar implants are now more commonly
used, it is still a challenge and Hemiarthroplasty eventually requires
revision to total hip replacement [33–35]. This procedure is still a good
option for some patients with guarded prognosis and short life ex-
pectancy.
In comparison to Hemiarthroplasty, total hip replacement elim-
inates chances of loosening, acetabular wear, residual hip and thigh
pain and has better long-term results. The availability and use of larger
femoral heads has substantially reduced the rate of dislocation in total
hip replacements [36,37]. Hip surgeons therefore prefer to perform
Total Hip replacement as single stage procedure in patients with or
without acetabular involvement [38–40]. The availability of modern
modular systems provides choices of femoral head sizes, calcar re-
placement femoral stems with trochanteric reattachments, variable
sizes of femoral component shaft, length and adjustment of femoral
anteversion. There are also options of using polished (cemented) or a
hydroxyapatite-coated collar at the bone-prosthesis junction for osseous
integration. Tumor resection in these patients can be carried out fol-
lowing oncological principles with wide margin resection for primary
tumors and palliative reconstruction avoiding extra-articular resection
for metastatic lesions. After appropriate resection, total hip replace-
ment is performed and the acetabulum and proximal femur is re-
constructed based on the amount of bony destruction on either side
(Fig. 4). Proximal femur replacement prosthesis is readily available and
in patients with spared greater trochanter it is subsequently reattached
to the endoprosthesis with the trochanteric reattachment plate and
screws or cable-grip wires. If trochanteric sparing is not possible, the
abductor mechanism is sutured to vastus lateralis and the fascia lata
[40].
Prosthetic replacement appears better then stabilization or fixation
as it allows immediate weight bearing, quick rehabilitation and su-
perior long-term results. Comparing the outcome of prosthetic re-
construction with intramedullary nailing and open reduction and fixa-
tion for proximal femur fractures in metastatic lesions of proximal
Fig. 2. 79 year-old, female with lytic lesion in left proximal femur. A: AP view
showing the lesion in prximal. part of left Femur. B: lateral view of the left Hip.
C: MRI of the left Femur showing the extent of the lesion and its confinement to
bone. D: left femur IM nailing was performed, histopathology confirmed Plasma
Cell tumor, at 2 years follow up, patient is fully ambulant with no pain or
residual disease.
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Femur, Stein et al. reported that prosthetic reconstruction was most
durable over time with no failures. Although blood loss and anesthesia
time was reported higher for prosthetic reconstruction as compared to
intramedullary nailing or ORIF, there was no difference in 30-day
systemic complication rates among three surgical strategies. Prosthetic
reconstruction however was associated with higher rate of infection
[41] and this has also been reported in other studies [42,43] Disloca-
tion is another complication of prosthetic replacement, with rates
varying from 1.7% to 20% [42,43]. High dislocation rate can be at-
tributed to the destruction and resection of soft tissues around the hip,
including the muscles and hip capsule in most cases. Availability and
use of large size femoral heads seems to reduce the risk of dislocation.
Recent introduction of dual mobility (dual articulation acetabular
component) in total hip replacement is a useful addition in hip surgeons
armamentarium. Dual mobility hip replacements has substantially re-
duced dislocation rate in primary and revision total hip replacements
and its use in tumor related hip surgery is getting increasingly popular
[44].
5. Conclusion
Surgical management of metastatic lesions of the Hip is complex
and major operative intervention. Location and extent of the lesion
should be carefully assessed by advanced imaging techniques.
Identification of primary tumor and Patient's medical condition needs
careful consideration. Objective assessment of patient's comorbidities
and cancer status can be done by the available scoring systems [45–47].
Surgical intervention must be planned in coordination with medical
oncologists and physicians for comprehensive perioperative manage-
ment. Experienced oncological and hip surgeons can perform en-
doprosthetic reconstruction around the hip in selected patients allowing
quicker rehabilitation. This reconstruction method is durable but with
inherent risks of infection and dislocation. Introduction of computer
based navigation and patient specific instrumentation has the potential
to increase accuracy of tumor resection and decrease the incidence of
implant-specific complications [48–50]. Poor cancer status, timing,
estimated life expectancy and available surgical expertise should be
considered in the choice of surgical strategy to optimize the outcome of
surgery in these patients.
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Fig. 3. 45-year-old male, known to have multiple myeloma, presented with
pain in left shoulder and right hip. A: x-ray Pelvis showing pathological fracture
right Femur. B: X-ray left Humerus with lytic lesion. C: MRI showing fracture
and the extent of the lesion in the proximal Femur. D: ORIF left proximal
Humerus with cement and right-sided proximal femur replacement with THR
with dual mobility acetabular cup was performed for complete pain relief and
function.
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